ALZHEIMER’S DISEASE IS COMPLEX.
AD wreaks havoc on our loved ones in painfully intimate ways. Abnormal protein accumulation, neuroinflammation and impaired neurotransmission are associated features.
Multifactorial diseases like AD require multifaceted management, and development teams that work just as aggressively as the disease itself.
AMYRIAD is developing drug treatments in conjunction with cutting-edge diagnostics, digital staging assessments and disease mitigation strategies.
OUR LEAD THERAPEUTIC CANDIDATE,
AD101 IS IN PREPARATION FOR PHASE 3 CLINICAL TRIALS.
Central to AMYRIAD is our drug development initiative.
Our efforts are focused on improving global function and cognition, the two key areas affected by AD.
Our 100 Series lead compound, AD101, is a small, synthetic molecule that enhances neurotransmission.
DIAGNOSTICS THAT RECOGNIZE FORM CONTROLS FUNCTION
At AMYRIAD our diagnostics efforts are aimed toward detecting 3-dimensional structural changes in proteins that result in dysfunctional activity, abnormal accumulation, and neuronal inflammation.
THE FUTURE IS DIGITAL
AMYRIAD is committed to modernizing current techniques for staging AD severity and assessing the impact of drug treatments. We are partnering with experts in digital technologies to transform 20th-century instruments for 21st-century patients.
LIFE IS A STRATEGY
AD has many forms and stages, so its treatment should too. AMYRIAD is dedicated to pursuing early diagnosis, disease mitigation strategies and therapeutic treatments that will improve patient function and quality of life